ReviewJournal of translational medicine2010
Cellular and vaccine therapeutic approaches for gliomas.
Review in Journal of translational medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01144247 (A Phase I Clinical Trial Evaluating Cellular Immunotherapy With Intratumoral Alloreactive Cytotoxic T Lymphocytes and Interleukin-2 for the Treatment of Recurrent Malignant Gliomas or Meningiomas), which is not on this map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I Clinical Trial Evaluating Cellular Immunotherapy With Intratumoral Alloreactive Cytotoxic T Lymphocytes and Interleukin-2 for the Treatment of Recurrent Malignant Gliomas or Meningiomas
Who cites it
14 citing papers in PubMed, 36 citations in OpenAlex.
- First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.Journal of translational medicine · 2018Trial
- Redefining Dendritic Cell Vaccines: Synergistically Co-priming DC and B Cells With Nanoparticles Loading Whole Cell Antigens Maximizes the Efficacy of DC Vaccines.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Advanced Cell Therapies for Glioblastoma.Frontiers in immunology · 2022Review
- Adoptive immunotherapies in neuro-oncology: classification, recent advances, and translational challenges.Acta bio-medica : Atenei Parmensis · 2020Article
- Antitumor and Immunomodulatory Activities of Ganoderma lucidum Polysaccharides in Glioma-Bearing Rats.Integrative cancer therapies · 2018Article
- Limiting glioma development by photodynamic therapy-generated macrophage vaccine and allo-stimulation: an in vivo histological study in rats.Journal of biomedical optics · 2018Article
- Fascin-1 knock-down of human glioma cells reduces their microvilli/filopodia while improving their susceptibility to lymphocyte-mediated cytotoxicity.American journal of translational research · 2015Article
- Vaccine therapies for patients with glioblastoma.Journal of neuro-oncology · 2014Review
- Glioma and glioblastoma - how much do we (not) know?Molecular and clinical oncology · 2013Review
- Intracerebral CpG immunotherapy with carbon nanotubes abrogates growth of subcutaneous melanomas in mice.Clinical cancer research : an official journal of the American Association for Cancer Research · 2012Article
- Passive immunotherapeutic strategies for the treatment of malignant gliomas.Neurosurgery clinics of North America · 2012Review
- Differential glioma-associated tumor antigen expression profiles of human glioma cells grown in hypoxia.PloS one · 2012Article
- Implementing preclinical study findings to protocol design: translational studies with alloreactive CTL for gliomas.American journal of translational research · 2012Article
- Lung cancer: a classic example of tumor escape and progression while providing opportunities for immunological intervention.Clinical & developmental immunology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Despite new additions to the standard of care therapy for high grade primary malignant brain tumors, the prognosis for patients with this disease is still poor. A small contingent of clinical researchers are focusing their efforts on testing the safety, feasibility and efficacy of experimental active and passive immunotherapy approaches for gliomas and are primarily conducting Phase I and II clinical trials. Few trials have advanced to the Phase III arena. Here we provide an overview of the cellular therapies and vaccine trials currently open for patient accrual obtained from a search of http://www.clinicaltrials.gov. The search was refined with terms that would identify the Phase I, II and III immunotherapy trials open for adult glioma patient accrual in the United States. From the list, those that are currently open for patient accrual are discussed in this review. A variety of adoptive immunotherapy trials using ex vivo activated effector cell preparations, cell-based and non-cell-based vaccines, and several combination passive and active immunotherapy approaches are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.